Polioviruses possess three major antigenic sites which have been located chemically and structurally on the particle. One of these sites, designated site 1, is strongly immunodominant for serotype 3, but highly immunorecessive for type 1. We report that monoclonal antibodies directed against site l of type 1 poliovirus may be isolated by an altered route of immunization of the donor mice. Site 1 is shown to be highly variable for type 1, but highly conserved for type 3 poliovirus, although the converse would be predicted from their immunodominance. The evidence presented suggests that the antigenic conservation is associated with a strong selective pressure for a proteolytic cleavage site within site 1 of type 3. As proteolytic cleavage results in the loss of the antigenicity of site 1 the presence of the cleavage site in a virus replicating in the gut in the presence of proteases would protect the virus from neutralizing antibodies directed against uncleared site I. The conservation of the site in type 3 is thus consistent with the view that site 1 is a significant target of a human as well as a murine immune response against type 3.
INTRODUCTION
Polioviruses occur in three antigenically stable serotypes, designated types 1, 2 and 3. We have previously reported studies of the antigenic structure of poliovirus type 3 involving the isolation and characterization of mutants resistant to neutralization by monoclonal antibodies (MAbs) Minor et al., 1983 Minor et al., , 1985 Minor et al., , 1986a . Three main sites to which neutralizing antibody could attach were identified. These were a sequence in VP1 from residues 89 to 100 with residues 166 and 253 of VP1 (designated site 1), a site including residues 164 to 172 of VP2 (site 2), and a third site (site 3) made up of residues 286 to 290 of VP1 with residues 58 and 59 of VP3. A site consisting of residues 77 and 79 of VP3 was also identified by a single antibody, and was assumed to form part of site 3, although no antibody was found which was affected by mutations in these residues as well as in residues forming part of site 3. The location and composition of these sites were consistent with the X-ray crystallographic structure of type 1 poliovirus .
Site 1 was found to be the target of most MAbs to native type 3 virus and MAbs to the other sites were isolated at an acceptable frequency only when splenocytes were taken from mice immunized by the intraperitoneal route with virus treated with trypsin, which destroys site 1 (Fricks et al., 1985; Icenogle et al., 1986) .
In contrast, it was found that only antibodies to sites 2 and 3 were obtained when splenocytes were taken from mice immunized by the intraperitoneal route with native type 1 poliovirus of the Sabin vaccine strain (Minor et al., 1986a) , a result consistent with the previous findings of other workers with both the Sabin vaccine strain and the Mahoney strain of type 1 poliovirus (Diamond et al., 1985; Blondel et al., 1986) . Only one antibody to site 1 of poliovirus type 1 has 0000-7679 © 1987 SGM P.D. MINOR AND OTHERS been reported hitherto (Blondel et al., 1983) . The difference between the serotypes regarding the immunodominance of site 1 was a surprising finding, as the viruses are believed to be structurally similar.
Major antigenic sites involved in virus neutralization might be expected to be highly variable between strains as a result of immune selection (Makoff et al., 1982; Wiley et al., 1981) and antibodies against such sites would be specific for a particular strain. It was therefore surprising that antibodies against the immunodominant site 1 of type 3 poliovirus were found to be more broadly reactive than antibodies against site 3 (Ferguson et al., 1982 Minor et al., 1985) . Similarly, sequential type 3 poliovirus strains isolated from a primary vaccinee showed signs of antigenic drift in sites 2 and 3, but not in site 1 (Minor et al., 1986b) . These findings suggest either that site 1 is not the major antigenic site so far as the human response to type 3 poliovirus is concerned (Icenogle et al., 1986) or that it is conserved for some functional reason.
This paper describes further studies of type 1 poliovirus in which MAbs directed against site 1 were isolated. Possible reasons for the conservation of site 1 of type 3 poliovirus during replication in humans were also examined.
METHODS
Virus and cell growth. Polioviruses were grown in HEp-2c cells as described previously (Minor, 1980) . Preparation of MAbs. Virus labelled with [3sS]methionine was grown and purified by sucrose density gradient centrifugation as described elsewhere (Ferguson et al., 1984) . BALB/c mice were immunized by injection of purified type 1 poliovirus of the Sabin strain directly into the spleen (Gearing et al., 1985) . Hybridomas were prepared and screened by the modified single radial diffusion (antigen blocking) test as described elsewhere (Ferguson et al., 1984) .
Isolation and characterization of antigenic mutants. Antigenic mutants were isolated by plaque formation on the HEp-2 cells, and examined for antigenic reactivity as described elsewhere .
Sequence determination ofRNA. This was carried out by the dideoxy chain termination primer extension method .
Trypsin treatment of viruses. Sucrose-purified preparations of poliovirus were incubated with trypsin (Difco) at pH 7-4 for 1 h at 37 °C. In some cases the reaction was stopped with a 10-fold excess of soybean trypsin inhibitor (Sigma).
SDS-potyacrylamide gel electrophoresis. SDS-polyacrylamide gel electrophoresis of [3sS]methionine-labelled virus and autoradiography were carried out as described in Minor (1980) except that the resolving gel was of uniform concentration, 15~ acrylamide, 0-075~ methylenebisacrylamide.
RESULTS

Preparation of MAbs specific for site 1 of type 1 poliovirus
Intraperitoneal immunization of mice with type 1 poliovirus yields MAbs directed to sites other than site 1 for both the Mahoney and Sabin strains of virus (Diamond et al., 1985; Blondel et al., 1986; Minor eta/., 1986a) . Mice were therefore immunized by direct injection of the Sabin strain of type 1 poliovirus into the spleen, a route which has been found in some cases to raise antibodies to antigenic sites which are not normally detected (Gearing et al., 1985) .
Trypsin treatment of the Sabin strain of type 1 poliovirus selectively destroys site 1 while the Mahoney strain of type 1 poliovirus is not affected (Fricks et al., 1985) . An antibody directed against site 1 of the Sabin strain of type 1 would therefore be expected to react with native but not trypsin-treated virus. Of 50 antibodies obtained initially, 12 were directed at site 1 by this criterion. Three MAbs (952, 955 and 956) were studied further. These antibodies were able to neutralize all mutants of the Sabin vaccine strain of type 1 poliovirus previously isolated (Minor et al., 1986a) and a mutant selected with 955 was resistant to antibodies 952 and 956 while still being neutralized by all previously examined antibodies. The antibodies were therefore directed against a site not previously identified. The mutant proved to have a substitution in VP1 at residue 100, which was a lysine in the parental strain and arginine in the mutant. This residue lies in a region homologous to site 1 of polioviruses of types 2 and 3 (Minor et al., 1986a) . The reactivity of antibodies 952, 955 and 956 with type 1 poliovirus, and the properties of mutants selected with them confirmed that they were directed against site 1 of poliovirus type 1. 
Strain specificity of MAbs against different sites of poliovirus types 1 and 3
The amino acid sequences of the Mahoney and Sabin strains of type 1 poliovirus are known to differ in the regions of VP1 corresponding to site 1 (Nomoto et al., 1982) . It was therefore of interest to establish whether Mahoney and other strains of type 1 poliovirus could be distinguished from the Sabin strain by their reactions with antibodies specific for site 1. Table 1 lists the reactions of 16 strains of poliovirus type 1 with a panel of eight MAbs raised against the Sabin type 1 vaccine strain of poliovirus, P1-LSC 2ab, including 952, 955 and 956, which were directed against site 1. The four strains V4, V5, V6 and V7 were obtained from vaccinees, and oligonucleotide maps indicated that they were closely related to the Sabin type 1 vaccine strain (data not shown). All other strains except Mahoney, the precursor of the Sabin type 1 strain, were unrelated to the Sabin strain on the basis of their oligonucleotide maps (data not shown). Only the Sabin vaccine strain P1-LSC 2ab and the vaccine-derived strains V6 and V7 were neutralized by the site 3-specific antibodies 423 and 424. The antibodies specific for site 2 neutralized 8, 10 and 6 of the 10 virus strains which were not related to the Sabin type vaccine strain. They also neutralized the precursor strain Pl/Mahoney and all of the strains from the vaccinees, in contrast to the antibodies directed against site 3. Site 2 therefore appeared to be less variable than site 3. However all three antibodies specific for site 1 were extremely strainspecific. All Sabin-derived strains so far tested, including the four shown in Table 1 , were effectively neutralized, while no other strain examined was sensitive, including P1/Mahoney.
The findings for MAbs specific for type 3 poliovirus are shown in Table 2 , which lists 13 strains of poliovirus type 3 and their reaction with a panel of MAbs raised against the Sabin type 3 vaccine strain or strains closely related to it (Ferguson et al., 1984; Minor et al., 1986a) . P3/Leon/USA/1937 is the virulent precursor of the Sabin type 3 strain P3/Leon/12al b. All other strains were shown to be unrelated to the Sabin strain P3/Leon/12alb or each other by oligonucleotide mapping (data not shown). The site recognized by a given antibody was identified by the isolation and characterization of antigenic variants of P3/Leon/12alb as previously described (Minor et al., 1986a) .
All six antibodies specific for site 3 neutralized P3/Leon/12a 1 b and all except one, 138, also neutralized P3/Leon/USA/1937, the precursor of the Sabin vaccine strain. All other strains tested were resistant to all six antibodies suggesting that site 3 of the Sabin vaccine strain and P3/Leon/USA/1937 differed significantly from site 3 of all of the remaining isolates. This was comparable to the findings for type 1 poliovirus presented in Table l . The two antibodies specific for site 2 neutralized three and four of the 11 strains unrelated to the Sabin vaccine strain respectively, suggesting that this site was rather less variable than site 3. The eight antibodies specific for site 1, however, neutralized 8, 6, 11, 9, 8, 8, 10 and 8 of the 11 strains unrelated to the Sabin vaccine strain of type 3 poliovirus, suggesting that this was the most conserved of the three antigenic sites examined. This contrasted with the findings for antibodies directed against site 1 of type 1 poliovirus, which were highly strain-specific.
Sequences of site 1 of t.vpe 1 and type 3 poliovirus
The highly strain-specific nature of the antibodies directed against site 1 of the Sabin vaccine strain of type I poliovirus suggested either that the sequence of site 1 was hypervariable between the strains examined or that the sequence of site 1 of the Sabin vaccine strain was unique, differing from that of all other strains. On the other hand, the broadly reactive nature of antibodies against the corresponding site of type 3 poliovirus suggests that its sequence was well conserved for all strains.
For the type 3 Sabin strain of poliovirus, site 1 has been shown to consist of the contiguous 12 amino acid sequence from residues 89 to 100 of VP1 with residues 166 and 253 of VP1. The sequences of the genomic RNA of the virus strains shown in Tables 1 and 2 were determined by primer extension sequencing through the region coding for residues 89 to 100 of type 3 or the homologous region of type 1, which includes residues 92 to 103. The resulting RNA sequences were translated into the amino acid sequences shown in Table 3 , which includes the consensus sequences for the type l and type 3 strains studied. Three out of 11 type 1 viruses had the consensus sequence in site 1, two differed by a single amino acid, five by two amino acids and one by three amino acids. Seven of 13 type 3 strains had the consensus sequence, four differed by a single amino acid, one by two amino acids and one by four amino acids. For the limited number of strains examined therefore, the sequence of site 1 was more variable in type 1 than in type 3, consistent with the observed difference in the specificity of the MAbs.
The Sabin strain of poliovirus type 1 has been shown to be sensitive to trypsin cleavage at the lysine residue at position 100 (Fricks et al., 1985) but the progenitor strain P1/Mahoney, which has a threonine at this position, is not sensitive (P. D. Minor, unpublished results). The Sabin strain of poliovirus type 3 has also been shown to be cleaved by trypsin in vitro (Icenogle et al., 1986) . Cleavage occurs at the arginine at residue 98 of VP1 and results in the destruction of antigenic site 1, without affecting the infectivity of the virion. It was striking that the arginine at residue 98 of VP1 of type 3 was conserved in all except two of the isolates, whereas the lysine at residue 100 of VP1 of type 1 was found in only two isolates.
Sensitivity of type 3 poliovirus to proteolytic enzymes
Site 1 of the Sabin strain of type 3 poliovirus has been shown to be sensitive to trypsin treatment in vitro. The natural site of replication of poliovirus is in the small intestine in a region rich in proteases, and it was thus of interest to determine whether unpassaged type 3 poliovirus 
* Amino acid residues are numbered from the N terminus of VP1 and are designated by the single letter code.
present in stool specimens was present in the trypsin-cleaved form and so resistant to antibodies to site I. Stool specimens from primary vaccinees were incubated either with no type 3 antibody, with a site 1 type 3 antibody or with a site 3 type 3 antibody. All specimens were also incubated with antibodies specific for type 1 and type 2 poliovirus, directed against sites other than site 1, to ensure neutralization of any type 1 or type 2 components. Samples were adsorbed to HEp-2c cell sheets for l h, after which the inocula and antibodies were removed by thorough washing and the cell sheets overlaid with 1% agar. The viruses were thus only exposed to antibody before adsorption to the cell sheet. Virus produced in the course of the plaque assay would be expected to regenerate an intact site 1, and thus be neutralized by the site 1 MAb. Plaques were counted after incubation at 35 °C for 4 days. The results are summarized in Table 4 for two samples from vaccinee DM, two samples from vaccinee KT1 and one sample from KT2, as well as for control native and trypsin-treated Sabin type 3 poliovirus.
It can be seen that under the conditions used, the tissue culture-grown virus was effectively neutralized by type 3-specific antibodies against either site 1 or site 3, but not by the type 1 and type 2 antibodies. As predicted, the trypsin-treated virus was not neutralized by the type 3 antibody specific for site 1, but was neutralized by the antibody specific for site 3. The type 3 virus present in the unpassaged stool specimens was also neutralized only by the type 3 antibody specific for site 3, and in this respect resembled the trypsin-treated control. Plaque plugs were picked from the plates, virus was eluted and subjected to an identical cycle of antibody treatment and plaque formation. The viruses from the plaque would be predicted to have regenerated an intact site 1, and in all cases were found to be neutralized by type 3 antibodies against both sites (data not shown). This demonstrated that the plaques which were originally picked did not consist of either mutant type 3 virus or virus of a different serotype. 
Variation in site 1 of type 3 during intestinal infection
Proteolytic cleavage of site 1 in vitro destroys its antigenic character. It is thus probable that antibodies directed against this site in the course of a human infection would be unable to recognize proteolytically cleaved virus replicating in the gut. There would therefore be a selective pressure in favour of virus retaining the proteolytic cleavage site and we have previously reported (Minor et al., 1986b) that successive isolates of type 3 poliovirus from a primary vaccinee varied in sites 2 and 3 but not site 1.
Direct evidence for a selective advantage in favour of type 3 poliovirus possessing a trypsinsensitive site 1 was obtained as a result of a recent outbreak of poliomyelitis in Finland, which was attributable to type 3 poliovirus of unusual antigenic properties (Magrath et al., 1986) , Most isolates were not neutralized by the available MAbs to site 1, and sequencing data showed some variation in this site compared to the Sabin type 3 vaccine strain, including a substitution of asparagine for arginine at residue 98. This substitution would be expected to render the virus insensitive to trypsin. Sequential isolates were taken from a number of infected individuals and examined for neutralization by MAbs (Huovilainen et al., 1987) . In at least three cases (AK, KA, VV) it was found that the virus initially excreted was resistant to neutralization by antibodies specific for site 1, but that later samples were neutralizable by one or two of these antibodies. The amino acid sequences of these isolates through the region of the genome coding for site 1 were deduced from the sequence of the genomic RNA, and are shown in Table 5 , with their ability to be neutralized by the site 1-specific antibodies 175 and 204. Neutralization by 175 was associated with the substitution ofa lysine for the asparagine at amino acid 98 of VP1 which is an arginine in the Sabin type 3 strain. Neutralization by 204 required that amino acid 99 was an alanine. It is likely that neutralization by antibody 204 also required that amino acid 98 was a lysine, in view of the previously recorded reactions of these antibodies with mutants Minor et al., 1985) . The substitution of a lysine for an asparagine, which occurred as a result of single base changes (data not shown), introduced a potential trypsin cleavage site in the same position as the trypsin cleavage site of the Sabin type 3 vaccine strain.
The trypsin sensitivity of early and late isolates was compared with that of the Sabin strain of type 3 poliovirus. Purified preparations of [3SS]methionine-labelled Sabin type 3 poliovirus and strains AK 60212, AK 25725 IaA and AK 25725 VIIaA were treated with 0, 0.05 ~tg/ml and 5 pg/ml trypsin at 37 °C for 1 h and then subjected to SDS-PAGE and autoradiography. The results in Fig. 1 demonstrate that as expected capsid protein VP1 of strain AK 60212 with an asparagine at residue 98 was not trypsin-sensitive. On the other hand, capsid protein VP1 of the Sabin type 3 strain with an arginine at residue 98, and AK 25725 IaA and AK 25725 VIIaA with a lysine at residue 98, were cleaved at both enzyme concentrations. No difference in the trypsin sensitivity of VP1 of the two isolates of AK 02575 was observed under these conditions.
In further experiments comparable to those described in Table 4 , it was found that MAb 175 was unable to neutralize unpassaged virus from stool specimen 25725 (not shown). This suggested that the virus was in the trypsin-cleaved form in the stool specimen, as expected from its sensitivity in vitro.
D I S C U S S I O N
The three-dimensional atomic structure of poliovirus type l revealed that the sequence of VP1 including residues 92 to 103 formed part of the most prominent feature at the pentameric apex of the icosahedral virus particle. The corresponding sequence of type 3 poliovirus which extends from residues 89 to 100 of VP1 has been shown to be a major antigenic site involved in virus neutralization, such that the majority of murine antibodies are directed against it Minor et al., 1983 Minor et al., , 1985 Minor et al., , 1986a Icenogle et al., 1986) . Previously however, only one antibody specific for this site has been described for type 1 (Blondel et al., 1983) , and it is not a major target of polyclonal murine antibodies (Icenogle et al., 1986) . The work described here confirms that murine antibodies directed against this sequence can be raised by an appropriate immunization schedule, although it remains unclear why, under other schedules, the site should be so poorly immunogenic for type 1 poliovirus compared to its dominance for type 3.
It was striking that the antibodies against site 1 were also extremely specific for the Sabin vaccine strain of type 1 poliovirus, and they have proved to be able to recognize strains obtained from vaccinees with great reliability, even where there was evidence of antigenic and genetic drift at other sites. It therefore appears that they may be suitable reagents for the identification of strains derived from the Sabin vaccine strain.
Immunodominant antigenic sites would be expected to be hypervariable as they would be subject to stronger selective pressures than immunorecessive sites. The conservation of the immunodominant site 1 of type 3 poliovirus compared to the variability of the immunorecessive site 1 of type 1 poliovirus was therefore surprising. However, a possible explanation is suggested by the finding that the antigenic properties of site 1 of the Sabin strains of either type 1 or type 3 poliovirus may be destroyed by trypsin without affecting virus viability (Fricks et al., 1985; Icenogle et al., 1986) . Type 3 poliovirus in the stools of vaccinees appears to be in the trypsincleaved form and to lack site l, as might be expected of a virus growing in an area with a high protease concentration. Antibodies generated against this site on native virus would therefore be unable to recognize any virus retaining the trypsin cleavage site in the gut, with the result that the site would not be subject to immune selection. More strikingly, the recent outbreak of poliomyelitis in Finland gave rise to sequential isolates from three individuals where trypsinsensitive virus was selected from strains which were initially resistant. The success of the virus lacking the proteolytic site in infecting the human population remains unexplained (Huovilainen et al., 1987) .
By this reasoning, the constancy of site 1 of type 3 poliovirus, particularly the arginine at amino acid 98, provides evidence that this site of type 3 poliovirus is recognized by the human immune response. Similarly the variability of site 1 of type I poliovirus, including the loss of lysine 100, implies that sensitivity to trypsin cleavage at this site confers no selective advantage on the virus. One possible explanation for this observation would be that site 1 is not a significant target for either the human or murine immune responses. The variability of the region could be explained by the finding that it forms a loop away from the regions believed to be of great significance for the core structure of the virus so that it is likely that it may vary more readily than other regions without compromising the viability of the structure. Alternative explanations can also be proposed, including the possibility that the cleaved form of site 1 is as potent as the uncleaved form in the induction of neutralizing antibodies. This remains to be examined further.
Finally, it is not clear whether virus circulating in the blood during the brief viraemic phase of poliovirus infection is proteolytically cleaved. If it is not, it implies that virus in the normal replication site (the gut) may present a significantly different antigenic profile to that in the viraemic state. It is recognized that over 80~ of cases of poliomyelitis in unimmunized populations can be attributed to infection with type I poliovirus (Nathanson & Martin, 1979) , while studies of the age of seroconversion imply that infection with all three serotypes occurs with approximately equal frequency (Fox, 1958) . This implies that infection with wild type 1 poliovirus is significantly more hazardous than infection with either wild type 2 or wild type 3 poliovirus. While there are many hypotheses which could explain this finding, it is possible that the differences in the immunodominance of the different antigenic structures play a part.
